Vertex Pharmaceuticals CEO Jeffrey M. Leiden Sells 45,000 Shares (VRTX)
Vertex Pharmaceuticals (NASDAQ:VRTX) CEO Jeffrey M. Leiden sold 45,000 shares of Vertex Pharmaceuticals stock on the open market in a transaction dated Thursday, January 16th. The stock was sold at an average price of $80.00, for a total value of $3,600,000.00. Following the sale, the chief executive officer now directly owns 182,925 shares in the company, valued at approximately $14,634,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 1.35% during mid-day trading on Friday, hitting $82.09. 1,978,362 shares of the company’s stock traded hands. Vertex Pharmaceuticals has a 52-week low of $43.57 and a 52-week high of $89.96. The stock has a 50-day moving average of $71.54 and a 200-day moving average of $74.76. The company’s market cap is $19.189 billion.
Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Tuesday, October 29th. The company reported ($0.32) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.33) by $0.01. The company had revenue of $222.00 million for the quarter, compared to the consensus estimate of $278.80 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The company’s revenue for the quarter was down 34.0% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $-2.62 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at UBS AG upgraded shares of Vertex Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday, January 6th. They now have a $99.00 price target on the stock, up previously from $84.00. Separately, analysts at Sanford C. Bernstein downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Thursday, October 31st. Finally, analysts at Credit Suisse cut their price target on shares of Vertex Pharmaceuticals from $80.00 to $78.00 in a research note to investors on Wednesday, October 30th. They now have a “neutral” rating on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $93.29.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.